diaDexus forms diagnostic license agreements with Human Genome Sciences.diaDexus, Inc. (S. San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden , CA) announced a license agreement with Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. , Inc. (Rockville, MD) under which Human Genome Sciences has acquired exclusive, worldwide rights to develop and commercialize diagnostic immunohistochemical tests based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins. diaDexus retains exclusive commercial rights for diagnostics based on TRAIL-R1 and TRAIL-R2 in other formats. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the terms of the agreement, diaDexus will receive an upfront payment, clinical and commercial milestone payments, and royalties. The TRAIL (tumor necrosis factor tumor necrosis factor n. Abbr. TNF A protein that is produced in the presence of an endotoxin, especially by monocytes and macrophages, is able to attack and destroy tumor cells, and exacerbates chronic inflammatory diseases. apoptosis-inducing ligand) Receptor-1 and TRAIL Receptor-2 proteins were discovered by Human Genome Sciences. diaDexus acquired diagnostic rights to TRAIL-R1 and TRAIL-R2 through an agreement with GlaxoSmithKline. Human Genome Sciences is currently conducting Phase 1 clinical trials phase 1 clinical trial Phase 1 study. See Phase study. to evaluate the safety and pharmacology of TRAIL-R1 monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing in patients with advanced tumors and a Phase 1 clinical trial in the United Kingdom to evaluate the safety and pharmacology of TRAIL-R2 monoclonal antibody in patients with advanced tumors. diaDexus is focused on the discovery, development and commercialization of novel, patent-protected diagnostic and therapeutic products with high clinical value. diaDexus utilizes genomics and bioinformatics to identify numerous disease-associated molecular targets. Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based drugs to patients. diaDexus +1-650-246-6400 www.diadexus.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion